Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

Summary

PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is shown in part A.

Timeline

Start

2018-11-27

Primary completion

2023-09-01

Completion

2025-09-01

Drugs

Indications